Revelation Biosciences, Inc. (REVB) 10-Year Financial Performance & Capital Metrics

REVB • • Industrial / General

HealthcareBiotechnologyInfectious DiseasesHepatitis & Viral Infections

AboutRevelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.Show more

Revenue $0
EBITDA -$8M +7.9%
Net Income -$15M -12405.6%
EPS (Diluted) -87.68 -942.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -264.85% -8379.7%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 5 (bottom 5%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM47.61%

EPS CAGR

10Y-

5Y-

3Y-

TTM94.08%

ROCE

10Y Avg-717.96%

5Y Avg-717.96%

3Y Avg-881.8%

Latest-140.46%

Peer Comparison

Hepatitis & Viral Infections

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ADMAADMA Biologics, Inc.	4.16B	17.50	21.60	65.15%	42.87%	48.57%	2.64%	0.24
CVACCureVac N.V.	1.05B	4.66	6.47	8.96%	37.93%	33.02%	7.95%	0.06
DWTXDogwood Therapeutics, Inc.	83.24M	2.80	-0.22			-49.37%		0.24
ALGSAligos Therapeutics, Inc.	44.22M	8.26	-0.39	-74.6%	-32.68%	-120.37%
INOInovio Pharmaceuticals, Inc.	108.55M	1.58	-0.40	-73.83%	-592.82%	-115.42%		0.17
BRNSBarinthus Biotherapeutics plc	29.81M	0.73	-0.47	17.66%	-408%	-89.73%		0.09
COCPCocrystal Pharma, Inc.	15.3M	1.11	-0.65			-126.11%		0.19
KLRSKalaris Therapeutics Inc	165.7M	8.86	-0.76			-170.84%

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	0	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-	-
Operating Expenses+	3.64K	3.8M	11.95M	10.86M	8.66M	7.98M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	3.64K	1.23M	5.04M	5.49M	4.51M	4.43M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	0	2.56M	6.91M	5.38M	4.15M	3.55M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	-1	0	0	0	0
Operating Income+	-3.64K	-3.8M	-11.95M	-10.86M	-8.66M	-7.98M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	-1042.38%	-2.15%	0.09%	0.2%	0.08%
EBITDA+	-3.64K	0	-11.93M	-10.84M	-8.63M	-7.95M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	1%	-	0.09%	0.2%	0.08%
D&A (Non-Cash Add-back)	0	3.8M	16.78K	25.05K	25.05K	27.92K
EBIT	-3.64K	-3.8M	-11.95M	-10.86M	-8.66M	-7.98M
Net Interest Income+	0	10.91K	-41.76K	0	0	0
Interest Income	0	10.91K	0	0	0	0
Interest Expense	0	0	41.76K	0	0	0
Other Income/Expense	0	126	-36.35K	34.96K	8.54M	-7.06M
Pretax Income+	-3.64K	-3.8M	-11.99M	-10.83M	-120.25K	-15.04M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-3.64K	-3.8M	-11.99M	-10.83M	-120.25K	-15.04M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	-1042.35%	-2.16%	0.1%	0.99%	-124.06%
Net Income (Continuing)	-3.64K	-3.8M	-11.99M	-10.83M	-120.25K	-15.04M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-6.72	-9032.69	-20400.00	-9643.37	-8.41	-87.68
EPS Growth %	-	-1343.15%	-1.26%	0.53%	1%	-9.43%
EPS (Basic)	-6.72	-9032.69	-20400.00	-9643.37	-8.41	-87.68
Diluted Shares Outstanding	542	181	588	1.12K	14.29K	171.51K
Basic Shares Outstanding	542	181	588	1.12K	14.29K	171.51K
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	0	4.62M	1.91M	5.41M	12.15M	6.57M
Cash & Short-Term Investments	0	4.49M	1.27M	5.25M	11.99M	6.5M
Cash Only	0	4.49M	1.27M	5.25M	11.99M	6.5M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	148.73K	160.3K	100.61K	49.5K
Total Non-Current Assets+	22.67K	0	130.14K	90.13K	65.08K	56.33K
Property, Plant & Equipment	0	0	130.14K	90.13K	65.08K	56.33K
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	22.67K	0	0	0	0	0
Total Assets+	22.67K	4.62M	2.04M	5.5M	12.21M	6.62M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	202.8%	-0.56%	1.69%	1.22%	-0.46%
Total Current Liabilities+	26.31K	1.21M	2.14M	4.45M	5.56M	1.91M
Accounts Payable	0	865.9K	596.26K	554.21K	1.36M	783.62K
Days Payables Outstanding	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0
Other Current Liabilities	26.31K	0	0	2.91M	3.44M	2.25K
Current Ratio	-	3.82x	0.89x	1.22x	2.18x	3.43x
Quick Ratio	-	3.82x	0.89x	1.22x	2.18x	3.43x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	0	0
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0
Total Liabilities	26.31K	1.21M	2.14M	4.45M	5.56M	1.91M
Total Debt+	0	0	16.75K	0	0	0
Net Debt	0	-4.49M	-1.26M	-5.25M	-11.99M	-6.5M
Debt / Equity	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-	-286.18x	-	-	-
Total Equity+	-3.64K	3.41M	-99.47K	1.05M	6.65M	4.71M
Equity Growth %	-	938.77%	-1.03%	11.58%	5.32%	-0.29%
Book Value per Share	-6.72	18899.95	-169.29	937.18	465.20	27.45
Total Shareholders' Equity	-3.64K	3.41M	-99.47K	1.05M	6.65M	4.71M
Common Stock	0	2.29K	282	77	265	522
Retained Earnings	-3.64K	-2.53M	-14.52M	-25.35M	-25.47M	-40.51M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	0	-215.07K	-11.09M	-11.22M	-7.29M	-18.32M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	-	-50.57%	-0.01%	0.35%	-1.51%
Net Income	-3.64K	-1.63M	-11.99M	-10.83M	-120.25K	-15.04M
Depreciation & Amortization	0	0	16.78K	25.05K	25.05K	27.92K
Stock-Based Compensation	0	0	470.88K	301.12K	155.72K	168.85K
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	0	1.5M	52.38K	14.96K	-8.33M	-56.44K
Working Capital Changes	3.64K	-80.5K	356.22K	-730.97K	982.13K	-3.42M
Change in Receivables	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0
Change in Payables	0	0	-269.64K	-666.04K	749.66K	-576.28K
Cash from Investing+	0	-74.04M	-131.96K	0	0	-19.17K
Capital Expenditures	0	0	-131.96K	0	0	-19.17K
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	-525.29K	0	0	0
Cash from Financing+	0	74.26M	8M	15.2M	14.03M	12.85M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	10K	0	0	11.54M	34	0
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	0	-215.07K	-11.22M	-11.22M	-7.29M	-18.34M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	-	-51.18%	0%	0.35%	-1.52%
FCF per Share	-	-1191.46	-19099.53	-9990.56	-509.89	-106.94
FCF Conversion (FCF/Net Income)	-	0.06x	0.93x	1.04x	60.59x	1.22x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-222.75%	-723.81%	-2272.77%	-3.12%	-264.85%
Interest Coverage	-	-	-286.18x	-	-	-
FCF Conversion	-	0.06x	0.93x	1.04x	60.59x	1.22x

Frequently Asked Questions

Growth & Financials

Revelation Biosciences, Inc. (REVB) grew revenue by 0.0% over the past year. Growth has been modest.

Revelation Biosciences, Inc. (REVB) reported a net loss of $8.1M for fiscal year 2024.

Dividend & Returns

Revelation Biosciences, Inc. (REVB) has a return on equity (ROE) of -264.9%. Negative ROE indicates the company is unprofitable.

Revelation Biosciences, Inc. (REVB) had negative free cash flow of $10.0M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener